Lyell Immunopharma, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
Lyell Immunopharma, Inc. (LYEL) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $66.33 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-03-12
- Lyell Immunopharma, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2025 was $66.33M, a 23.92% decline from fiscal 2024.
- Lyell Immunopharma, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $87.18M.
- Lyell Immunopharma, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $0.00.
- Lyell Immunopharma, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|
| 2025-12-31 | $66.33M 10-K · filed 2026-03-12 |
| 2024-12-31 | $87.18M 10-K · filed 2026-03-12 |
| 2023-12-31 | $0.00 10-K · filed 2026-03-12 |
| 2022-12-31 | $0.00 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |